Efek kombinasi Bevacizumab dan Deksametason Sodium Fosfat Intravitreal pada ketebalan makula sentral dan tajam penglihatan pasien edema makula diabetik derajat sedang–berat = Effects of combined intravitreal bevacizumab and dexamethasone sodium phosphate for the treatment of moderate to severe diabetic macular edema
| Main Authors: | Vega Casalita, author, Add author: Joedo Prihartono, supervisor |
|---|---|
| Format: | Bachelors Doctoral |
| Terbitan: |
Fakultas Kedokteran Universitas Indonesia
, 2019
|
| Subjects: | |
| Online Access: |
https://lib.ui.ac.id/detail?id=20500775 |
| ctrlnum |
20500775 |
|---|---|
| fullrecord |
<?xml version="1.0"?>
<dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><type>Thesis:Bachelors</type><title>Efek kombinasi Bevacizumab dan Deksametason Sodium Fosfat Intravitreal pada ketebalan makula sentral dan tajam penglihatan pasien edema makula diabetik derajat sedang–berat = Effects of combined intravitreal bevacizumab and dexamethasone sodium phosphate for the treatment of moderate to severe diabetic macular edema</title><creator>Vega Casalita, author</creator><creator>Add author: Joedo Prihartono, supervisor</creator><publisher>Fakultas Kedokteran Universitas Indonesia</publisher><date>2019</date><subject>Macular Edema -- therapy</subject><subject/><description>Latar Belakang: Terapi bevacizumab tunggal kurang efektif dalam mengobati edema makula diabetik (DME) derajat sedang-berat, sehingga berpotensi meningkatkan jumlah reinjeksi dan risiko kehilangan penglihatan permanen akibat edema makula berkepanjangan. Pada kasus tersebut diperlukan terapi adjuvan. Selain vascular endothelial growth factor (VEGF), mediator inflamasi juga berperan penting pada patogenesis DME.
Tujuan: Mengetahui perbedaan nilai ketebalan makula sentral (CMT) dan tajam penglihatan terbaik dengan koreksi (BCVA) sebelum dan sesudah pemberian injeksi intravitreal kombinasi bevacizumab dan deksametason sodium fosfat (DSP) pada DME sedang-berat.
Metodologi: Pada studi eksperimental one group lengan tunggal ini, dilakukan injeksi kombinasi bevacizumab 1,25 mg dan DSP 0,5 mg intravitreal pada 18 mata DME dengan CMT >400 μm. Dilakukan evaluasi BCVA dan CMT pada 1 bulan pasca injeksi, serta peningkatan tekanan intraokular (TIO) dan efek samping.
Hasil: Pada 1 bulan didapatkan penurunan CMT yang signifikan dari 572,8±119,3 μm menjadi 376,3±132,3 μm. Terdapat perbaikan BCVA yang signifikan dari 0,76(0,26-1,80) logMAR menjadi 0.56 (0.12-1.02) logMAR (p<0.001). Tidak terdapat peningkatan TIO dan derajat katarak yang bermakna pada semua subjek.
Kesimpulan: Terapi kombinasi bevacizumab dan DSP pada pasien DME derajat sedang-berat berpotensi meningkatkan efektivitas anatomis pada follow up 1 bulan. Terapi kombinasi bermanfaat dalam menurunkan edema segera serta meningkatkan dan stabilisasi tajam penglihatan.
......Backgrounds: Bevacizumab monotherapy is less effective in treating moderate to severe diabetic macular edema (DME), thus potentially increasing the amount of reinjection and risk of permanent visual loss due to prolonged macular edema. In such cases adjuvant therapy is needed. In addition to vascular endothelial growth factor (VEGF), inflammatory mediators also play an important role in the pathogenesis of DME.
Objectives: To identify the response of intravitreal bevacizumab combined with dexamethasone sodium phosphate (DSP) in treating moderate to severe DME.
Methods: In this non comparative experimental study, 18 eyes with DME having CMT >400 μm received intravitreal bevacizumab (1.25 mg) combined with DSP (0.5 mg). Best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated at 1 week and 1 month, as well as increased IOP and other side effects.
Results: Comparing across follow up periods (pre, one week, one month post injection) there were statistically significant differences of CMT (572.8±119.3 vs 432,44±103,45 vs 376.3±133.3 μm, p<0.001) and BCVA ( 0.76 (0.26-1.80) vs 0,55(0,14-1,80) vs 0.56 (0.12-1.02), p<0.001) LogMAR. No significant increase in IOP and degree of cataract were observed in all subjects.
Conclusions: Adding intravitreal DSP as an adjuvant to bevacizumab for the treatment of moderate to severe DME potentially enhance anatomical effectiveness, especially in the first week after injection. Combination therapy is useful in reducing edema immediately and improvement and stabilization of visual acuity.</description><identifier>https://lib.ui.ac.id/detail?id=20500775</identifier><recordID>20500775</recordID></dc>
|
| format |
Thesis:Bachelors Thesis Thesis:Doctoral |
| author |
Vega Casalita, author Add author: Joedo Prihartono, supervisor |
| title |
Efek kombinasi Bevacizumab dan Deksametason Sodium Fosfat Intravitreal pada ketebalan makula sentral dan tajam penglihatan pasien edema makula diabetik derajat sedang–berat = Effects of combined intravitreal bevacizumab and dexamethasone sodium phosphate for the treatment of moderate to severe diabetic macular edema |
| publisher |
Fakultas Kedokteran Universitas Indonesia |
| publishDate |
2019 |
| topic |
Macular Edema -- therapy |
| url |
https://lib.ui.ac.id/detail?id=20500775 |
| contents |
Latar Belakang: Terapi bevacizumab tunggal kurang efektif dalam mengobati edema makula diabetik (DME) derajat sedang-berat, sehingga berpotensi meningkatkan jumlah reinjeksi dan risiko kehilangan penglihatan permanen akibat edema makula berkepanjangan. Pada kasus tersebut diperlukan terapi adjuvan. Selain vascular endothelial growth factor (VEGF), mediator inflamasi juga berperan penting pada patogenesis DME.
Tujuan: Mengetahui perbedaan nilai ketebalan makula sentral (CMT) dan tajam penglihatan terbaik dengan koreksi (BCVA) sebelum dan sesudah pemberian injeksi intravitreal kombinasi bevacizumab dan deksametason sodium fosfat (DSP) pada DME sedang-berat.
Metodologi: Pada studi eksperimental one group lengan tunggal ini, dilakukan injeksi kombinasi bevacizumab 1,25 mg dan DSP 0,5 mg intravitreal pada 18 mata DME dengan CMT >400 μm. Dilakukan evaluasi BCVA dan CMT pada 1 bulan pasca injeksi, serta peningkatan tekanan intraokular (TIO) dan efek samping.
Hasil: Pada 1 bulan didapatkan penurunan CMT yang signifikan dari 572,8±119,3 μm menjadi 376,3±132,3 μm. Terdapat perbaikan BCVA yang signifikan dari 0,76(0,26-1,80) logMAR menjadi 0.56 (0.12-1.02) logMAR (p<0.001). Tidak terdapat peningkatan TIO dan derajat katarak yang bermakna pada semua subjek.
Kesimpulan: Terapi kombinasi bevacizumab dan DSP pada pasien DME derajat sedang-berat berpotensi meningkatkan efektivitas anatomis pada follow up 1 bulan. Terapi kombinasi bermanfaat dalam menurunkan edema segera serta meningkatkan dan stabilisasi tajam penglihatan.
......Backgrounds: Bevacizumab monotherapy is less effective in treating moderate to severe diabetic macular edema (DME), thus potentially increasing the amount of reinjection and risk of permanent visual loss due to prolonged macular edema. In such cases adjuvant therapy is needed. In addition to vascular endothelial growth factor (VEGF), inflammatory mediators also play an important role in the pathogenesis of DME.
Objectives: To identify the response of intravitreal bevacizumab combined with dexamethasone sodium phosphate (DSP) in treating moderate to severe DME.
Methods: In this non comparative experimental study, 18 eyes with DME having CMT >400 μm received intravitreal bevacizumab (1.25 mg) combined with DSP (0.5 mg). Best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated at 1 week and 1 month, as well as increased IOP and other side effects.
Results: Comparing across follow up periods (pre, one week, one month post injection) there were statistically significant differences of CMT (572.8±119.3 vs 432,44±103,45 vs 376.3±133.3 μm, p<0.001) and BCVA ( 0.76 (0.26-1.80) vs 0,55(0,14-1,80) vs 0.56 (0.12-1.02), p<0.001) LogMAR. No significant increase in IOP and degree of cataract were observed in all subjects.
Conclusions: Adding intravitreal DSP as an adjuvant to bevacizumab for the treatment of moderate to severe DME potentially enhance anatomical effectiveness, especially in the first week after injection. Combination therapy is useful in reducing edema immediately and improvement and stabilization of visual acuity. |
| id |
IOS18069.20500775 |
| institution |
Universitas Indonesia |
| institution_id |
51 |
| institution_type |
library:university library |
| library |
Perpustakaan Universitas Indonesia |
| library_id |
492 |
| collection |
Repository Disertasi (Open) Universitas Indonesia |
| repository_id |
18069 |
| city |
KOTA DEPOK |
| province |
JAWA BARAT |
| repoId |
IOS18069 |
| first_indexed |
2022-12-14T04:39:05Z |
| last_indexed |
2022-12-14T04:39:05Z |
| recordtype |
dc |
| merged_child_boolean |
1 |
| _version_ |
1752210147133882368 |
| score |
17.609869 |